Unicycive Therapeutics Inc (NASDAQ:UNCY)’s traded shares stood at 0.5 million during the latest session, with the company’s beta value hitting 2.36. At the last check today, the stock’s price was $0.38, to imply an increase of 0.50% or $0.0 in intraday trading. The UNCY share’s 52-week high remains $1.82, putting it -378.95% down since that peak but still an impressive 47.37% since price per share fell to its 52-week low of $0.20. The company has a valuation of $36.04M, with an average of 1.7 million shares in intraday trading volume over the past 10 days and average of 2.44 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Unicycive Therapeutics Inc (UNCY), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give UNCY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
After registering a 0.50% upside in the latest session, Unicycive Therapeutics Inc (UNCY) has traded red over the past five days. The 5-day price performance for the stock is -8.37%, and 8.10% over 30 days. With these gigs, the year-to-date price performance is -55.99%. Short interest in Unicycive Therapeutics Inc (NASDAQ:UNCY) saw shorts transact 0.38 million shares and set a 0.11 days time to cover.
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Looking at statistics comparing Unicycive Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Unicycive Therapeutics Inc (UNCY) shares are -73.11% down over the last 6 months, with its year-to-date growth rate lower than industry average at 0.00% against 19.40%. Revenue is forecast to shrink -15.40% this quarter before jumping 40.90% for the next one.
UNCY Dividends
Unicycive Therapeutics Inc has its next earnings report out on 2024-Aug-14. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
Unicycive Therapeutics Inc insiders hold 6.73% of total outstanding shares, with institutional holders owning 30.24% of the shares at 32.42% float percentage. In total, 30.24% institutions holds shares in the company, led by VIVO CAPITAL, LLC. As of 2024-06-30, the company held over 3.47 million shares (or 9.9395% of shares), all amounting to roughly $1.74 million.
The next major institution holding the largest number of shares is LOGOS GLOBAL MANAGEMENT LP with 3.47 million shares, or about 9.9389% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.74 million.
